The female hormonal system is extremely sensitive, and even the smallest biochemical shift can have a dramatic impact on everyday life. The length of the cycle, the amount of menstrual bleeding, the regularity of ovulation, mood swings, and energy levels are all indicators that reflect how internal hormonal regulation works. Modern research is increasingly showing that these conditions are not separate phenomena, but part of the same complex system, and if one area is out of balance, it can affect the entire cycle like a domino effect.
Symptoms commonly experienced by women, such as PMS, irregular cycles, painful ovulation, low progesterone levels or difficulty conceiving, often stem from the same basic biochemical imbalance: impaired insulin sensitivity, an imbalance in ovarian MI/DCI (inositols) or a cellular micronutrient deficiency. According to research, symptoms improve permanently when the underlying metabolic processes are regulated, which is why the role of inositols and the appropriate micronutrient supply is in focus.
Maintaining female hormonal balance is the result of complex biochemical processes. The regulation of the menstrual cycle, ovulation, ovarian function, insulin sensitivity, cellular energy metabolism, and steroid hormone synthesis are all system elements that are closely interconnected. Although there may be many factors behind hormonal complaints, one of the most important and best-supported areas of research is the role of inositols in ovarian function , especially in PCOS, but also in menstrual disorders, PMS, and fertility difficulties in general.
Hormonal balance depends not only on the amount of hormones, but also on how sensitively the cells respond to hormonal signals. For this, micronutrients that participate as coenzymes or regulatory molecules in the synthesis of hormones, intracellular signaling processes and normal ovarian function are essential. Zinc, selenium, vitamin B6, folate, vitamin D3 and copper are all elements that directly influence the quality of follicle maturation, the accuracy of ovulation signaling and the efficiency of insulin receptors.
Micronutrient deficiencies often occur insidiously, yet they can cause profound changes: luteal phase stability may deteriorate, progesterone levels may fluctuate, androgen production may increase, and egg quality may decrease. Since the process of follicular maturation lasts more than 90 days, everything that happens during this time, from stress levels to nutrition to micronutrient intake, directly affects the quality of the cycle. Therefore, targeted micronutrient supplementation is at least as important as inositol supplementation to truly restore hormonal balance.
In line with this new scientific consensus , vSherpa Female Balance+ formula is based on a physiological 40:1 ratio of myo-inositol to D-chiro-inositol , along with additional proven micronutrients (zinc, selenium, vitamin D3, vitamin B6, folate, copper, vanadium). Together, these ingredients provide systemic support that addresses multiple aspects of female hormonal balance:
- ovarian function ,
- insulin sensitivity ,
- normalization of androgens ,
- ovulation and cycle regularity ,
- mood and PMS symptoms ,
- thyroid and cellular antioxidant status .
Restoring hormonal balance is not an immediate process , as the female endocrine system operates cyclically and responds to support in biological cycles of follicular maturation-ovulation-luteal phase, which are connected, approximately 90 days. The vast majority of clinical studies, whether it concerns myo-inositol, D-chiro-inositol, vitamin D, zinc and selenium, have shown significant improvements in ovulatory function, normalization of the LH/FSH ratio, reduction of insulin resistance, reduction of testosterone levels and regularization of the cycle after a continuous intake period of 8-12 weeks . The active ingredients in the vSherpa Female Balance+ formula are therefore not quick solutions: their effect is fully achieved if they are used daily for at least 3 months , in accordance with the natural regeneration rhythm of the ovaries. Therefore , consistent, daily intake is one of the most important factors for success when using the product.
Hormonal balance is always managed from the bottom up: first, insulin and glucose response must be stabilized, then the ovarian MI/DCI balance must be restored, and then key micronutrients must be replenished, without which cells cannot respond properly to hormonal signals. Based on clinical data, the three most important pillars are: regular intake of the MI/DCI 40:1 combination, optimal levels of vitamin D3 and zinc, and provision of vitamin B6, which reduces PMS and stress. Together, these can create a biochemical environment in which ovulation can return, the cycle is regulated, and symptoms gradually decrease.
Below is a detailed presentation of the most important studies, and then at the end of the article I will summarize and show how these results fit into the professional concept of vSherpa Female Balance+ .
The role of myo-inositol and D-chiro-inositol in female hormonal balance
The physiological MI/DCI ratio: why exactly 40:1?
Under natural conditions in the ovary, the ratio of myo-inositol to D-chiro-inositol is close to 40:1 . This is no coincidence:
- Myo-inositol is a secondary messenger of the FSH signaling pathway → necessary for follicular maturation and ovulation.
- D-chiro-inositol is involved in insulin signaling and is necessary, but too high a level inhibits aromatase , leading to androgen excess and ovulation problems.
In PCOS, this ratio is upset: the ovaries produce too much DCI and too little MI → as a result, ovulation is impaired, androgen levels increase, and insulin sensitivity worsens.
That's why vSherpa Female Balance+ contains the clinically proven 40:1 MI/DCI combination.
PMS is often caused by luteal phase deficiency, low levels of vitamin B6 and zinc, and serotonin metabolism disorders. The underlying causes of cycle disorders are usually ovarian MI deficiency and insulin resistance – as high insulin levels increase androgen production, which inhibits the process of follicle maturation and prevents ovulation. Infertility difficulties often result from a combination of these: egg maturation is slower, follicle quality deteriorates, ovulation becomes irregular or absent. These are all conditions that the MI/DCI combination and micronutrient supplementation work most effectively on.
Detailed, professional overview of prominent studies
1. Pustotina et al. (2024) – 40:1 ratio in PCOS A phenotype
Gynecologic and Obstetric Investigation
In the study, 34 women with PCOS (Rotterdam A – the most pronounced hormonal abnormality) were followed for 3 months with 2255 mg of myo-inositol + 50 mg of D-chiro-inositol (40:1) daily.
The control group received lifestyle advice but no inositol.
Results:
- Significant decrease in LH/FSH ratio
- Reduction in testosterone and androstenedione levels
- Improvement of insulin resistance (HOMA-IR)
- A 12-week follow-up is not sufficient to examine clinical changes such as:
- Restoring cycle regularity
- Return of ovulation
- Reduction in mood symptoms
Conclusion: The 40:1 inositol combination comprehensively improves hormonal and metabolic function , not only in mild but also in severe PCOS.
2. Nordio & Proietti (2012) – comparison of different MI/DCI ratios
This study is one of the most important clinical evidences for the 40:1 ratio .
Participants: 56 women with PCOS (8 women/group)
Tested ratios: 1:3.5 – 2.5:1 – 5:1 – 20:1 – 40:1 – 80:1
Dose: MI 2x2000 mg/day, adjusted according to DCI ratio
Duration: 3 months
Results:
- Only the 40:1 ratio fully restored ovulation.
- High DCI ratio (>1:5) caused worse ovarian response and worsening hormonal parameters.
- In the 40:1 group:
- strong LH/FSH normalization
- decreased androgenicity
- reduction of insulin resistance
Conclusion: The 40:1 ratio most effectively reconstructs the physiological ovarian MI/DCI ratio.
3. Bizzarri et al. (2023) – mechanistic background: why is too much DCI dangerous?
The article highlights:
- In PCOS, the ovaries produce too much DCI → androgen excess .
- Excessive DCI intake inhibits aromatase , which converts androgens into estrogen → cycle disruption and anovulation.
- The physiological ratio is 40:1 (MI:DCI).
This article provides the scientific basis for the fact that other ratios (e.g. 5:1, 10:1, 1:1) may be downright harmful. According to the authors, excessive DCI intake and ratios that favor DCI may adversely affect ovarian steroidogenesis, so a MI/DCI ratio close to physiology (approximately 40:1) seems reasonable.
4. Fitz et al. (2024) – Meta-analysis of 16 RCTs
The meta-analysis, which processed data from more than 30 studies and 2,230 participants , clearly states:
AI effects:
- improving hormonal balance
- increase ovulation rate
- normalization of ovarian function
Effects of DCI:
- metabolic marker improvement
- increasing insulin sensitivity
Combination – 40:1:
- the strongest hormonal and insulin resistance-improving effect
- cycle arrangement
- reducing androgen levels
Conclusion: the combination is more effective than either monodrug alone. According to the authors, inositols show promising effects, especially with regard to insulin resistance and some hormonal parameters, but the quality and consistency of the evidence is limited, so the place of therapy is not yet completely clear.
5. Dinicola et al. (2022) – mechanistic evidence
The article describes in detail:
- MI : essential for follicular maturation and FSH signaling pathway function.
- DCI : element of the insulin signaling pathway, aromatase inhibitor.
- In PCOS, MI deficiency develops in the ovaries → ovulation disorder.
- The 40:1 combination restores ovarian MI levels → normalizes the cycle.
6. Unfer et al. (2020) – restoration of ovulation in 8–12 weeks
This article summarizes that:
- The MI/DCI combination can restore ovulation within 8–12 weeks .
- It reduces androgenicity and the LH/FSH ratio.
- Normalizes the follicle maturation process.
This proves that the 3-month course of the product is an appropriate duration.
7. Kachhawa et al. (2021) – in young women with PCOS
Participants: 100 women with PCOS
Intervention: MI+DCI for 3 months
Results:
- cycle regularity: improved from 37% to 88%
- significant reduction in insulin resistance
- Mood symptoms also decreased
8. Gerli (2007) – ovulation and IUI success
196 women , 3 months, MI 4000 mg/day + 400 mcg folic acid
Results:
- better egg quality
- higher ovulation rate
- Improving IUI success rates
9. Ciotta (2011) – oocyte quality before IVF
Participants: 42 women with PCOS
Intervention: MI 4 g/day + folic acid for 3 months
Results:
- oocyte morphology improved
- multiple mature follicles
- better fertilization rate
10. Alanazi & Shah (2024) – MI+DCI vs. metformin
120 women with PCOS
- Group 1: MI+DCI (40:1)
- Group 2: metformin
Results:
- HOMA-IR decreased in both groups
- MI+DCI improved mood/stress indicators more
- fewer side effects
- better cycle regularity
The role of additional active ingredients in the Female Balance+ formula
Zinc
- According to RCTs, it improves insulin resistance in PCOS.
- It plays a role in the function of the luteal phase and follicular maturation.
Selenium
- According to meta-analyses, it improves glycemic control.
- Thyroid support → indirect cycle regulation.
Vitamin B6
- Several meta-analyses confirm the reduction of PMS symptoms .
- Coenzyme role in the synthesis of neurotransmitters and hormones.
Vitamin D
- According to RCTs, it improves ovarian morphology and insulin sensitivity in PCOS.
- It is a key molecule in the female cycle and immune system.
Folic acid (folate)
- Homocysteine reduction
- Follicular maturation support
Summary: how the vSherpa Female Balance+ formula is built on this
Research shows that one of the strongest and safest ways to support female hormonal balance is a 40:1 combination of myo-inositol and D-chiro-inositol , which is backed by over 15 years of clinical data.
vSherpa Female Balance+ complements this scientific foundation:
- with zinc (insulin sensitivity + luteal phase support)
- with selenium (thyroid + antioxidant status)
- With vitamin D3 (ovarian function + immunomodulation)
- With vitamin B6 (mood + PMS)
- with folate (homocysteine + ovulation)
- with copper and vanadium (microcirculation + insulin signaling supplementation)
Based on the clinical results and mechanistic relationships cited in the article , Female Balance+ is a complex female formula that can:
- regulate the LH/FSH ratio,
- reduce testosterone and androgen levels,
- improve insulin sensitivity,
- restore ovulation,
- to regularize the cycle,
- improve well-being and PMS symptoms,
- support healthy ovarian function.
Female Balance+ is not just a dietary supplement, but a hormone support system based on a scientific formula that, based on the most modern research, helps restore the natural balance of the female body. However, restoring hormonal balance is not just about supplements, it’s also about understanding your body’s signals and aligning your daily routine with your cycle. Regular MI/DCI supplementation, adequate levels of vitamin D3, zinc and vitamin B6 intake, stable blood sugar levels, minimizing stress, and improving sleep quality are all factors that can dramatically reduce PMS, support ovulation, and regulate your cycle. The female hormonal system is a collaborative, regenerative system — when given scientifically proven support and a consistent daily routine.
References
Pustotina, O., Myers, S., Unfer, V., et al. (2024). The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. Gynecologic and Obstetric Investigation, 89(2), 131–139.
Nordio, M., & Proietti, E. (2012). The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. European Review for Medical and Pharmacological Sciences, 16(5), 575–581.
Bizzarri, Monti, Piombarolo, Angeloni, Verna, et al. (2023). Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecological Endocrinology.
Fitz, Victoria., et al. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism, 109(6), 1630–1646.
Dinicola, S., et al. (2022). Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Functioning: A Review of the Evidence. Nutrients, 15(8), 1875.
Unfer, V., et al. (2020). Inositols in Polycystic Ovary Syndrome: An Overview on the Advances. International Journal of Endocrinology, 2020.
Kachhawa, G., et al. (2021). Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and insulin resistance in young women with PCOS: A randomized open-label study. International Journal of Gynecology & Obstetrics, 158(2), 278–284.
Gerli, S., et al. (2007). Myo-inositol administration improves ovulation induction and intrauterine insemination in patients with PCOS: A prospective, controlled, randomized trial. European Review for Medical and Pharmacological Sciences, 11(5), 347–354.
Ciotta, L., et al. (2011). Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: A double-blind trial. European Review for Medical and Pharmacological Sciences, 15(5), 509–514.
Alanazi, M., & Shah, M. (2024). Comparative efficacy of combined myo-inositol and D-chiro-inositol with metformin in patients with polycystic ovary syndrome. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(4), 877–889.
Sources of additional nutrients (zinc, selenium, B6, vitamin D, folate)
Jamilian, M., et al. (2016). Effects of zinc supplementation on markers of insulin resistance and lipid profiles in women with PCOS: A randomized, double-blind, placebo-controlled trial. Biological Trace Element Research, 170(2), 271–278.
Wojcik, M., et al. (2020). The Role of Zinc in Selected Female Reproductive System Disorders. Nutrients, 12(8), 2464.
Zhao, J., et al. (2023). Effects of selenium supplementation on Polycystic Ovary Syndrome: A systematic review and meta-analysis. BMC Endocrine Disorders, 23, 33.
Jamilian, M., et al. (2020). The effects of selenium supplementation on glycemic control, serum lipids, and oxidative stress in infertile women with PCOS. Clinical Nutrition ESPEN, 40, 146–151.
Zhu, Z., et al. (2022). Vitamin D supplementation in the treatment of PCOS: A meta-analysis of randomized controlled trials. Heliyon, 8(12), e11845.
Voulgaris, N., et al. (2024). Effects of Vitamin D3 Treatment on Polycystic Ovary Symptoms: A randomized trial. Nutrients, 17(7), 1246.
Samiepour, S., et al. (2016). Effects of vitamin B6 on premenstrual syndrome: A systematic review and meta-analysis. Journal of Chemical and Pharmaceutical Sciences, 9(3), 1346–1353.
Behroozi, F., et al. (2009). Pyridoxine (vitamin B6) and premenstrual syndrome: A randomized clinical trial. European Psychiatry, 24(S1), 4103.
